The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE

OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8

COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
APPLIED GENETIC TECHNOL CORP COM 03820J100 2,669 1,404,515 SH   SOLE   1,404,515 0 0
EIGER BIOPHARMACEUTICALS INC COM 28249U105 3,970 764,918 SH   SOLE   764,918 0 0
GLAUKOS CORP COM 377322102 15,565 350,264 SH   SOLE   350,264 0 0
VENUS CONCEPT INC COM 92332W105 1,120 658,657 SH   SOLE   658,657 0 0
DARE BIOSCIENCE INC COM 23666P101 124 62,065 SH   SOLE   62,065 0 0
THE REALREAL COM 88339P101 27,331 2,354,080 SH   SOLE   2,354,080 0 0
PMV PHARMACEUTICALS INC COM 69353Y103 74,726 3,234,911 SH   SOLE   3,234,911 0 0
C3.AI CL A 12468P104 27,087 866,774 SH   SOLE   866,774 0 0
SERA PROGNOSTICS CLASS A COM 81749D107 16,600 2,416,241 SH   SOLE   2,416,241 0 0